Introduction {#S1}
============

The involvement of the central nervous system (CNS) by hematologic malignancies is considered a major complication in patients with B- or T-cell lymphomas and in patients with acute lymphoid or myeloid leukemia ([@B1]). Neoplastic cell infiltration into the CNS may cause extensive neurological damage and can be progressive and fatal if it is not detected in time ([@B2], [@B3]). Meningeal infiltration by neoplastic cells occurs in approximately 5--15% of patients with leukemia and lymphoma ([@B4]). The involvement of the CNS can occur through dissemination of neoplastic cells through arteries, perineural and perivascular spaces, and infiltration of malignant cells from solid tumors ([@B4]--[@B6]).

Currently, the main tools used for detection of CNS infiltration by neoplastic cells include neurological clinical assessment, neuroimaging studies, and cytomorphology ([@B7]). Symptoms of CNS infiltration may be present in several conditions other than hematologic malignancies, the clinical manifestations are late and usually occur in advanced stages of disease ([@B7]). Some neuroimaging techniques, such as magnetic resonance imaging, are sensitive but have low specificity ([@B8]). Cytological examination of the cerebrospinal fluid (CSF) is considered a gold standard technique; however, it has low sensitivity with false positive results ranging from 20 to 60%, especially in low-cellularity samples ([@B9], [@B10]), which can delay diagnosis and the correct treatment of patients ([@B7], [@B11]).

Laboratory techniques with greater accuracy and sensitivity include molecular biology, molecular genetics, and flow cytometry (FC) ([@B7], [@B12]). FC complements cytology as a technique to test the CSF ([@B3], [@B13]--[@B15]). Cytometry can enhance the possibility of diagnosing lymphomas in the CSF, because it is able to detect abnormal cells in samples containing only 0.9% of monoclonal B-lymphocytes ([@B2], [@B16], [@B17]). Currently, in patients with clinical suspicion of CNS infiltration by neoplastic cells, cytology, and immunophenotyping by FC are the techniques recommended by the National Comprehensive Cancer Network ([@B18]).

Recent advances have shown that the use of multiparameter FC, such as 10-parameter single-tube detection, has considerably increased the specificity and sensitivity in detecting cells with abnormal phenotypes ([@B1], [@B14], [@B15], [@B17], [@B19]). Nonetheless, in most cases, the CSF has low cellularity with rapid cell degeneration. Therefore, recent studies have suggested some storage and transport guidelines, as well as sample preparation and staining protocols, to improve the quality of results ([@B1]).

Objective {#S1-1}
---------

The purpose of this diagnostic accuracy study is to evaluate the diagnostic performance of FC using a cell stabilizer for sample preservation compared to cytomorphology in the detection of CNS infiltration by lymphoid and hematologic neoplasms.

Materials and Methods {#S2}
=====================

Study Design, Participants, and Ethics {#S2-1}
--------------------------------------

This is a diagnostic accuracy study of FC results compared to cytomorphology as the gold standard technique, in the diagnosis of CNS infiltration by neoplastic cells. Participants were all patients who had their tissue samples tested by FC between January 2014 and December 2016 in the same institution. To be included in this study, patients should have clinical suspicion or be under follow up for hematological malignancy, or they suffered from neurological conditions, such as encephalitis, epilepsy, seizures, among others (the study of the CSF was performed to rule out any hypothesis of oncohematological disease). All patients underwent examination of CSF cells by FC.

The Institutional Review Board reviewed the study protocol and approved the use of data collected for this study. The human tissue and fluid samples analyzed were obtained from patients routinely subjected to immunophenotyping in a clinical FC laboratory for diagnosis of hematologic neoplasms, irrespective of this study. The study did not offer any direct benefits to patients or interfere with patient diagnosis or treatment.

Procedures {#S2-2}
----------

In order to preserve and prolong cell viability, the samples submitted for immunophenotyping were collected in cell stabilizer Transfix, in a tube containing the anticoagulant ethylenediaminetetracetic acid (EDTA), observing the ratio of 1:10 Tranfix/CSF and a volume ranging between 3 and 5 ml.

In cases of suspected lymphoproliferative disease and other clinical conditions, the staining strategy initially used for immunophenotyping was the Euroflow Small Sample Tube, with the antibodies shown in Table [1](#T1){ref-type="table"}. Patients with suspected infiltration by acute myeloid leukemia (AML), multiple myeloma, and acute B- and T-cell lymphoid leukemia were stained according to Table [2](#T2){ref-type="table"}. All antibodies were standardized, titrated, and validated by our laboratory.

###### 

Antibodies used for staining in the cases of suspicion of lymphoproliferative disease.

  Fluorochrome   DLPC            Clone               Manufacturer
  -------------- --------------- ------------------- ------------------
  FITC           CD8^+^ lambda   UCHT-4/polyclonal   Cytognos
  PE             CD56^+^ kappa   N901/polyclonal     Cytognos
  PERCP-Cy5.5    CD4             SK3                 Becton Dickinson
  PC7            CD19            J3-119              Beckman Coulter
  APC            CD3^+^ CD14     SK7/MφP9            Becton Dickinson
  APC-H7         CD38            HB7                 Becton Dickinson
  V450           CD20            L27                 Becton Dickinson
  V500           CD45            2D1                 Becton Dickinson

*FITC, fluorescein isothiocyanate; PE, phycoerythrin; PERCP-Cy5.5, phycoerythrin and cyanine dye; PC7, phycoerythrin-Cy7; APC, allophycocyanin; APC-H7, allophycocyanin H7*.

###### 

Antibodies used to investigate infiltration of hematologic malignancy in the central nervous system.

  Fluorochrome   B-ALL         Clone      AML                                 Clone      T-ALL         Clone      MM                                  Clone      Manufacturer
  -------------- ------------- ---------- ----------------------------------- ---------- ------------- ---------- ----------------------------------- ---------- --------------
  FITC           CD38          T16        [^a^](#tfn1){ref-type="table-fn"}   --         CD8           UCHT-4     CD38                                T16        Cytognos
  PE             CD56          N901       CD56                                N901       CD4           N901       CD56                                N901       Cytognos
  PERCP-Cy5.5    CD34          8G12       CD34                                8G12       CD34          8G12       [^a^](#tfn1){ref-type="table-fn"}   --         BD
  PC7            CD19          J3-119     CD117                               104D2D1    CD19          J3-119     CD19                                J3-119     BC
  APC            CD3^+^ CD14   SK7/MφP9   CD3^+^ CD14                         SK7/MφP9   CD3^+^ CD14   SK7/MφP9   CD3^+^ CD14                         SK7/MφP9   BD
  APC-H7         CD10          HB7        CD38                                HB7        CD38          HB7        [^a^](#tfn1){ref-type="table-fn"}   --         BD
  V450           CD20          L27        CD20                                L27        CD3cy         UCHT1      CD45                                2D1        BD
  V500           CD45          2D1        CD45                                2D1        CD45          2D1        CD138                               MI15       BD

*FITC, fluorescein isothiocyanate; PE, phycoerythrin; PERCP-Cy5.5, phycoerythrin and cyanine dye; PC7, phycoerythrin-Cy7; APC, allophycocyanin; APC-H7, allophycocyanin H7; BC, Beckman Couter; BD, Becton Dickinson; AML, acute myeloid leukemia; T-ALL, T-cell lymphoblastic leukemia; B-ALL, B-cell lymphoblastic leukemia*.

*^a^Empty spaces that can be filled in by previously markers known upon diagnosis and that can help investigate infiltration*.

Cytomorphology and FC {#S2-3}
---------------------

The cell count was performed approximately 30 min after puncture using a Fuchs-Rosenthal chamber and sample cellularity ranged between 0 and 908 cells/μl.

For slides preparation, we used cytocentrifugation at 1,000 rpm, for 5 min, using 200 μl of fresh CSF samples. Samples were stained according to the Leishmann method. Each case was interpreted by an experienced cytomorphologist who was unaware of the results of FC. Samples were considered negative in the absence of morphologically anomalous population. The results were considered positive when there was the presence of cells with atypical characteristics, such as high nucleus cytoplasm and presence of nucleolus.

According to the standard technical procedure, the cell samples were then centrifuged, now at a speed of 1,100 rpm, for 10 min, washed with 10 ml of phosphate buffer saline (PBS) + 2% fetal bovine serum (FBS). For clinical suspicion of infiltration of mature B-cell neoplasms, the washing procedure was repeated to eliminate proteins, which could interfere in detection of clonality with kappa and lambda light chain, and/or prevent unspecific staining.

The cell pellet was then stained with fluorochrome conjugates of monoclonal antibodies, and incubated for 20 min, at room temperature, and protected from light. Red blood cell lysis was performed (whenever necessary) with an ammonium chloride buffer for 5 min; cells were washed with 3 ml PBS + 2% FBS and resuspended in 0.5 ml PBS. Finally, the stained samples were immediately acquired in the Becton Dickinson FACS Canto II flow cytometer. Data analysis was performed using the Infinicyt software (Cytognos).

Statistical Analysis {#S2-4}
--------------------

Cytomorphology and FC results were compared using absolute and relative frequencies, and the agreement between methods was verified using kappa and diagnostic measures (sensitivity and specificity) ([@B20]). Cytomorphology was considered the gold standard technique. Statistical analyses were performed with SPSS, version 22.0 for Windows (SPSS Inc., Chicago, IL, USA).

Results {#S3}
=======

Between January 2014 and December 2016, 414 CSF samples (239, or 57.7% were men) were analyzed by FC and cytomorphology to investigate for CNS infiltration by hematological malignancy. The mean age was 48.5 years (range of 2--90 years).

Patients {#S3-1}
--------

Of the patients, 306 were clinically suspected of or being followed up for hematological malignancy, and 108 had other clinical conditions, such as encephalitis, epilepsy, seizures, among others. Of the 414 samples tested, 342 showed no immunophenotypic changes suggestive of CNS infiltration by hematological malignancies. Even in 335 samples who had low cellularity (\<5 cells/μl) defined by the Fuchs-Rosenthal global chamber count, FC was able to detect T-, B-, natural killer (NK)-lymphocytes, and monocytes (Table [3](#T3){ref-type="table"}).

###### 

Frequency of population detected by flow cytometry.

  Cerebrospinal fluid (CSF) cell count   Number of cases   Frequency of population in CSF                   
  -------------------------------------- ----------------- -------------------------------- ------- ------- ------
  0                                      104               96.9                             83.6    50.0    7.0
  1 cells/μl                             143               99.3                             94.4    73.4    23.8
  2 cells/μl                             35                100.0                            100.0   88.6    37.1
  3 cells/μl                             18                100.0                            100.0   83.3    61.1
  4--5 cells/μl                          11                100.0                            100.0   100.0   45.5

Negative FC Results {#S3-2}
-------------------

Comparing the 342 negative FC samples (Figure [1](#F1){ref-type="fig"}) with the morphological samples, 304 were also negative in the cytomorphological test. Only 2 samples showed positive cytomorphology for neoplastic cells, while 9 had inconclusive results in the same test. Morphological testing was not possible in 3 samples due to low cellularity, and 24 samples were missing an order for chemical and cytological analyses.

![Negative flow cytometry result for suspected central nervous fluid (CSF) infiltration by hematological malignancies. Presumptive diagnosis: central nervous system disorder. **(A,B)** Normal forward-scattered light (FSC size) and side-scattered light (complexity---SSC); **(C--E)** normal antigenic expression of CD3 in T-lymphocytes, CD4 and CD8 expression in CD3^+^CD4^+^ and CD3^+^CD8^+^ lymphocyte subtypes, CD14 expression in monocytes and CD38 expression and CD56^+^CD3^−^ natural killer (NK) cells; **(F,G)** polyclonal CD19^+^CD20^+^ B-lymphoid population for kappa (73%) and lambda (27%) light chains. Sample with 3 leukocytes/mm^3^ and 1 red blood cell/mm^3^, acquisition of 8,425 events in the FACS Canto II (Becton Dickinson), and analysis performed with the software Infinicyt (Cytognos). The frequency of populations in the viable cell region and CD45^+^ (3,385 events) was 68.6% CD3 T-lymphocytes---in that, 52.6% CD4 T-lymphocytes and 13.9% CD8 T-lymphocytes; 0.9% NK cells; 0.7% mature and polyclonal B-lymphocytes (kappa/lambda ratio: 2.38); and 29.8% monocyte lineage cells.](fmed-05-00070-g001){#F1}

Positive FC Results {#S3-3}
-------------------

Immunophenotypic abnormalities suggestive of CNS infiltration by hematological malignancies were found in 72 cases studied. Among the positive cases, 33 samples were classified as non-Hodgkin B-cell lymphoma (B-NHL, Figure [2](#F2){ref-type="fig"}); 10 as B-cell lymphoblastic leukemia (Figure [3](#F3){ref-type="fig"}); 1 blastic plasmacytoid dendritic cell neoplasm; 9 with T-cell lymphoblastic leukemia (Figure [4](#F4){ref-type="fig"}); 2 T/NK-cell lymphoblastic leukemia; 4 blastic plasmacytoid dendritic cell neoplasms, and 13 showed abnormal immature myeloid population (AML) (Figure [5](#F5){ref-type="fig"}).

![Flow cytometry results of suspected central nervous system infiltration by B-cell non-Hodgkin lymphoma. Presumptive diagnosis: B-cell non-Hodgkin lymphoma. **(A,B)** Normal forward-scattered light (FSC size) and side-scattered light (complexity---SSC); **(C)** mature CD19^+^ and CD20^+^ B-lymphoid population; **(D)** mature monoclonal lambda-light-chain-expressing B-lymphoid population. Sample collected in Transfix^®^/ethylenediaminetetracetic acid with an approximate volume of 5 ml and 2 leukocytes/mm^3^ and 0 red blood cells/mm^3^. Samples with 8,575 events acquired in Canto II (Becton Dickinson) and analyzed using the Infinicyt software (Cytognos). Frequency of populations in the viable cell region and CD45^+^ cell (1,000 events).](fmed-05-00070-g002){#F2}

![Flow cytometry results of suspected central nervous system infiltration by B-cell acute lymphoblastic leukemia. Presumptive diagnosis: suspected B-cell lymphoblastic leukemia. **(A)** Forward-scattered light (FSC size) and side-scattered light (complexity---SSC); **(B)** low-complexity blast population weakly expressing CD45 (light blue); **(C)** population of CD19^+^ and CD10^+^ B-lymphoid blasts; **(D)** strong expression of CD58 and moderate expression of CD38 in blast population; **(E)** CD10^+^ and CD34^+^ expression; **(F)** strong expression of CD10 in blast population. Sample collected in Transfix^®^/ethylenediaminetetracetic acid with an approximate volume of 5 ml and 3 leukocytes/mm^3^ and 0 red blood cells/mm^3^. Samples with 20,904 events acquired in Canto II (Becton Dickinson) and analyzed using the Infinicyt software (Cytognos). The frequency of populations in the viable cell region and CD45^+^ was 14,210 events.](fmed-05-00070-g003){#F3}

![Flow cytometry results of suspected central nervous system infiltration by T-cell acute lymphoblastic leukemia. Presumptive diagnosis: T-cell lymphoblastic leukemia. **(A)** Forward-scattered light (FSC size) and side-scattered light (complexity---SSC); **(B)** low-complexity blast population (light blue) moderately/strongly expressing CD45; **(C)** CD4/CD8 double positive blast population; **(D)** intracytoplasmic CD3-positive and surface CD3-negative blasts. Sample collected in Transfix/ethylenediaminetetracetic acid with an approximate volume of 5 ml and 3 leukocytes/mm^3^ and 10 red blood cells/mm^3^. Samples with 11,575 events acquired in Canto II (Becton Dickinson) and analyzed using the Infinicyt software (Cytognos). The frequency of populations in the viable cell region and CD45^+^ cell was 7,913 events.](fmed-05-00070-g004){#F4}

![Flow cytometry results of suspected central nervous system infiltration by immature myeloid population. Presumptive diagnosis: acute myeloid leukemia. **(A)** Forward-scattered light (FSC size) and side-scattered light (complexity---SSC); **(B)** low-complexity blast population (light blue) strongly expressing CD45; **(C)** blast population with abnormal CD117 expression and absent CD34 expression. Sample collected in Transfix/ethylenediaminetetracetic acid with an approximate volume of 5 ml and 1 leukocyte/mm^3^ and 2 red blood cells/mm^3^. Samples with 6,375 events acquired in Canto II (Becton Dickinson) and analyzed using the Infinicyt software (Cytognos). The frequency of populations in the viable cell region and CD45^+^ was 2,541 events.](fmed-05-00070-g005){#F5}

In respect to the 72 positive FC samples, 35 were also positive on the cytomorphology test, 2 were inconclusive, 29 were negative, 1 sample was not processed due to low cellularity, and in 5 cases, there were no samples available because the attending physician did not fill in the request for chemical and cytological testing. Interestingly, the CNS infiltration by hematological malignancies was identified even in samples with \<5 cells/μl that represented 55.6% (40/72) of positive FC tests (*p* \< 0.001, Figure [6](#F6){ref-type="fig"}). Furthermore, in these 40 positive FC samples, 57.5% (23/40) had negative cytomorphology tests.

![Positive results for flow cytometry and results found for cytomorphology.](fmed-05-00070-g006){#F6}

In the study of 414 cases, 370 presented positive or negative results for FC and cytomorphology. FC showed higher sensitivity and specificity for 370 samples when compared to cytomorphology, particularly in cases with cellularity under 5 leukocytes/mm^3^ (Table [4](#T4){ref-type="table"}). This scenario of low cellularity represented 75.1% of the samples analyzed (311/414) (Figure [7](#F7){ref-type="fig"}).

###### 

FC versus cytomorphology in the detection of infiltration of the central nervous system by hematologic malignancy.

                         Cytomorphology                                                                             
  ----------- ---------- ---------------- ------ ------ ----- ------ ---------------- -------------- -------------- ------
  ≤5 mm^3^    Negative   274              88.1   0      0.0   274    88.1             0.518          100            92.3
  Positive    23         7.4              14     4.5    37    11.9   (0.351; 0.685)   (76.8; 100)    (88.6; 95)     
  Total       297        95.5             14     4.5    311   100                                                   
                                                                                                                    
  \>5 mm^3^   Negative   30               50.8   2      3.4   32     54.2             0.724          91.3           83.3
  Positive    6          10.2             21     35.6   27    45.8   (0.548; 0.9)     (72; 98.9)     (67.2; 93.6)   
  Total       36         61.0             23     39.0   59    100                                                   
                                                                                                                    
  Total       Negative   304              82.2   2      0.5   306    82.7             0.649          94.6           91.3
  Positive    29         7.8              35     9.5    64    17.3   (0.537; 0.761)   (81.8; 99.3)   (87.7; 94.1)   
  Total       333        90.0             37     10.0   370   100                                                   

*FC, flow cytometry; Sens., sensitivity; Spec., specificity*.

![Samples grouped according to cellularity.](fmed-05-00070-g007){#F7}

Discussion {#S4}
==========

This study reports the technical improvements made to increase test accuracy, sample stability, and compare CSF analysis by FC and cytomorphology. The technical procedures of FC have been recently improved aiming to increase test reliability and make better use of samples. Our study showed that 72 samples had a phenotype compatible with infiltration by hematologic disease, whereas cytology was positive in 35 cases. Thus, FC was much more accurate and sensitive when compared with cytomorphology, primarily in low-cellularity and low-volume samples.

The investigation of CSF infiltration by hematologic neoplasms by conventional morphologic study has low sensitivity even when associated with neuroimaging studies, as well as neurological signs and symptoms. Despite the high specificity of cytomorphology, the literature reports false negative results range between 20 and 60% ([@B2], [@B16], [@B21]). Currently, conventional cytology tests yield positive results for neoplastic cells at concentrations starting at 5% ([@B22]). However, the cytomorphological analysis may be impaired because of the paucity of cells in CSF. Moreover, the identification of neoplastic cells in CSF can be a challenge due to similarities between benign and malignant cells. Several studies have demonstrated a significant increase in sensitivity of meningeal infiltration detection in patients with hematologic malignancies when the samples are evaluated by FC comparing the cytomorphology, ratifying the importance of immunophenotyping in CSF analysis ([@B21], [@B23]--[@B25]).

Due to higher sensitivity, FC is important to detect occult or subclinical CNS involvement during maintenance therapy and clinical follow-up, especially when cytomorphology is negative. The detection of subclinical CNS involvement is associated with poor prognosis and a higher risk of relapse in acute lymphoblastic leukemia and B-cell lymphomas ([@B2], [@B16], [@B24], [@B26]).

However, FC still has some limitations for CSF testing due to low cellularity, aggravated by small samples and poor cell viability. In addition to these limitations, peripheral blood contamination could alter results, and it is very difficult to identify. Thus, CSF immunophenotyping requires specific technical procedures to be correctly conducted ([@B1]). In our data, 6 samples of 72 positive cases by FC were suggestive of contamination, and despite this, the ability to detect neoplastic cells in CSF by FC is greater than cytomorphology regardless of whether the cells are primary of the CNS or the result from peripheral blood contamination by puncture trauma. We know that this possibility of contamination is aggravated at the time of diagnosis of acute leukemias, when the neoplastic cells circulating in the peripheral blood may be in greater numbers. However, in the central neural system post-treatment evaluations of acute leukemias, the presence of circulating neoplastic cells is rare, which may indicate that the immunophenotypic findings suggest CNS infiltration and not contamination of the material at this clinical time.

In our study, FC was able to identify no neoplastic CSF cells and infiltrating neoplastic cells even in samples with low-cellularity and low-volume that represented 75.1% of our samples (Figure [7](#F7){ref-type="fig"}). Interestingly, even in CSF with no cells defined by Fuchs-Rosenthal chamber count, FCM was able to detect T-, B-, NK-lymphocytes, and monocytes (Table [3](#T3){ref-type="table"}). As expected, the detection capability is proportional to CSF cells concentration. Our data showed that in a CSF with 2 cells/μl all T-cells and monocytes can be identified, and for NK-, B-lymphocytes the cellularity requirement varies between 3 and 5 cells/μl.

Altogether, these results support previous observations that FC is more sensitive than cytomorphology ([@B2], [@B21]), and that FC was able to detect CSF disease more frequently than cytomorphology ([@B16]). In this study, FC could detect CSF involvement in 11 samples while cytomorphology was able to detect only 1 case. The explanation to the higher sensitivity is that cytomorphology shows positive or suspicious results only in samples with increased cellularity. All this progress has been possible due to technical standardization for better cell concentration in a single tube, and updating of our immunophenotyping protocol, from 4 to 8 colors and 13 parameters. A better cell concentration provided satisfactory results even in samples with low cellularity and the change in immunophenotyping protocol allowed the staining in a single tube, increasing sensibility. The use of analysis software, such as Infinicyt, enabled a more accurate and reproducible data analysis, removing interfering factors, such as doublets, degenerated cells, and unspecific staining. Moreover, the use of the cell stabilizer Transfix allowed the receipt of samples from distant centers, avoiding stability problems. However, the cell stabilizer cannot be used for morphological analysis.

One of the major challenges faced by laboratories in CSF processing is rapid cell degeneration in samples. Thirty minutes after collection, the cell count starts to decrease significantly ([@B27]). The use of collection media is recommended to solve this problem ([@B1]). The two media used by most laboratories are the Roswell Park Memorial Institute medium and Transfix (Cytomarl, UK).

Transfix is a stabilizer that prevents cell loss and reduces autofluorescence. Some studies showed that using Transfix in CSF samples prevents cell loss and allows the sample to be stored for 18--72 h until it is processed ([@B1], [@B27]). Moreover, the complexity features of lymphocytes are maintained, cell autofluorescence decreases, and cell fixation does not interfere with monoclonal antibody staining. However, there is a decrease in the size and complexity of granulocyte and monocyte populations in case of prolonged storage in Transfix, which could hinder cytomorphological testing ([@B27]). FC is a powerful and sensitive technique for testing CSF with suspected infiltration of lymphoma or leukemia. With all these improvements, it was possible to increase the accuracy and sensitivity of the detection of B- and T-lymphocytes, and their subtypes (CD3^+^, CD3^+^CD4^+^, and CD3^+^CD8^+^), as well as NK cells and monocytes, even in samples with low cellularity and low volume, and both in non-neoplastic and neoplastic samples.

Our data corroborate the literature findings and allow us to conclude that FC is a highly sensitive tool for detection of hematologic neoplasms cells in CSF, especially in low-level CNS involvement. This information could be useful for close monitoring of patients, changes in therapy strategy, and identify patients with high risk of relapse.

Conclusion {#S5}
==========

In this study, we demonstrated that the CSF can be used for disease detection and screening of major leukocyte populations, even in low-volume and low-cellularity samples. This is possible if the sample is collected in a medium that preserves sample stability, immunophenotyping is performed with technical procedures specific for CSF samples, if appropriate immunophenotyping panels and a flow cytometer with 8-color/13-parameter configuration are used, as well as modern data analysis software.
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